| |
Isotechnika Inc.
Based in Edmonton, Canada, Isotechnika Inc. focuses
primarily on Research and Development of immune-modulatory medications.
In May 2006 Lux Biosciences signed a license agreement with Isotechnika
that gave access to LX211 (Isotechnika code ISA247) as well as the
active ingredient exclusively and worldwide for ophthalmic indications.
For further information please visit
www.isotechnika.com
Rutgers, The State University of New Jersey, and the Center for
Biomaterials
Established in 1766, Rutgers is America's eighth oldest institution of
higher learning and one of the nation's premier public research
universities. Serving more than 50,000 students on campuses in Camden,
Newark and New Brunswick/Piscataway, Rutgers offers more than 280
bachelor's, master's, doctoral and professional degree programs. The
university is home to 30 degree-granting schools and colleges, and more
than 150 specialized centers and institutes. With 320,000 living alumni,
Rutgers graduates are major contributors to all sectors of contemporary
life.
The New Jersey Center for Biomaterials, directed by Professor Joachim
Kohn, is a research consortium of three universities (Rutgers, New
Jersey Institute of Technology, and University of Medicine and Dentistry
of New Jersey), about 20 corporate partners including large and small
companies with interests in biomaterials science, and a diverse group of
research-active faculty. Established in 1997, the New Jersey Center for
Biomaterials has grown into a major, federally funded research center
with an extensive biomaterials patent portfolio. So far, six companies
have licensed biomaterials technologies developed at the Center.
For further information please visit
www.njbiomaterials.org
University of Missouri - Kansas City
Lux
Biosciences has established a research collaboration with the University
of Missouri - Kansas City and with Professor Ashim Mitra, Chairman,
Division of Pharmaceutical Sciences at the University of Missouri -
Kansas City. Dr. Mitra is an internationally recognized expert in the
field of ocular drug delivery and translational research in
ophthalmology. For further information please visit
http://pharmacy.umkc.edu/New/pharm/MITRA.html
The
National Eye Institute (National Institutes of Health)
Lux Biosciences has collaborated with the National Eye
Institute in the preclinical evaluation of its next generation
calcineurin inhibitor. In addition, a CsA-eluting silicone matrix
implant similar to LX201 has originally been developed by researchers at
the NEI. This implant is being tested clinically at NEI in severe dry
eye secondary to graft versus host disease. For further information
please visit
www.nei.nih.gov
© 2008 Lux
Biosciences, Inc. All rights reserved.
Web
Terms |
